GlassScriptPhysician profile
Rebecca S Gray
NPI 1366778144
$2,413.85
in general payments reported to CMS, 2019-2025
24 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $897 · 2022: $475 · 2023: $403 · 2024: $230 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $478.76 | 2021-2025 | Breztri, Airsupra, Nexium |
| Lilly USA, LLC | $353.27 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $352.00 | 2021-2023 | |
| Novo Nordisk INC | $208.51 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $158.50 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Celltrion USA INC. | $136.97 | 2025 | Zymfentra |
| Takeda Pharmaceuticals U.S.A., INC. | $86.52 | 2021-2022 | |
| Pfizer INC. | $73.66 | 2021-2022 | |
| Exact Sciences Corporation | $68.84 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $59.01 | 2021-2022 | |
| Merz North America, INC. | $56.67 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.45 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.10 | 2021 | |
| Astellas Pharma US INC | $37.62 | 2022-2023 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $36.77 | 2021-2022 | |
| Smith+Nephew, INC. | $33.53 | 2024 | Legion Revision |
| Xeris Pharmaceuticals, INC. | $31.01 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.72 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $19.70 | 2021 | |
| Tandem Diabetes Care, INC. | $18.62 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Almatica Pharma LLC | $15.08 | 2021 | |
| Insulet Corporation | $13.13 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.